MX390786B - Métodos y composiciones para tratar somnolencia excesiva. - Google Patents

Métodos y composiciones para tratar somnolencia excesiva.

Info

Publication number
MX390786B
MX390786B MX2019014409A MX2019014409A MX390786B MX 390786 B MX390786 B MX 390786B MX 2019014409 A MX2019014409 A MX 2019014409A MX 2019014409 A MX2019014409 A MX 2019014409A MX 390786 B MX390786 B MX 390786B
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating excessive
excessive sleepiness
sleepiness
Prior art date
Application number
MX2019014409A
Other languages
English (en)
Other versions
MX2019014409A (es
Inventor
Lawrence Patrick Carter
Yuan Lu
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64455104&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX390786(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of MX2019014409A publication Critical patent/MX2019014409A/es
Publication of MX390786B publication Critical patent/MX390786B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invencion esta relacionada con compuestos de carbamoil fenilalaninol y metodos para usar los mismos para tratar trastornos; la invencion esta ademas relacionada con el desarrollo de metodos para tratar somnolencia excesiva en un sujeto, por ejemplo, debido a narcolepsia o apnea obstructiva del sueno, con el resultado sorprendente de que niveles "normales de desvelo se logran con base en pruebas de somnolencia objetivas y subjetivas estandar.
MX2019014409A 2017-06-02 2018-06-01 Métodos y composiciones para tratar somnolencia excesiva. MX390786B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762514176P 2017-06-02 2017-06-02
PCT/US2018/035532 WO2018222954A1 (en) 2017-06-02 2018-06-01 Methods and compositions for treating excessive sleepiness

Publications (2)

Publication Number Publication Date
MX2019014409A MX2019014409A (es) 2022-03-17
MX390786B true MX390786B (es) 2025-03-21

Family

ID=64455104

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014409A MX390786B (es) 2017-06-02 2018-06-01 Métodos y composiciones para tratar somnolencia excesiva.

Country Status (12)

Country Link
US (7) US10959976B2 (es)
EP (1) EP3630072A4 (es)
JP (1) JP2020528075A (es)
KR (3) KR102726728B1 (es)
CN (1) CN111201014A (es)
AU (1) AU2018278332B2 (es)
BR (1) BR112019025286A2 (es)
CA (1) CA3065522A1 (es)
MX (1) MX390786B (es)
MY (1) MY203401A (es)
PH (1) PH12019502723A1 (es)
WO (1) WO2018222954A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
WO2021001457A1 (en) * 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
US10940133B1 (en) * 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
MX2024002483A (es) * 2021-09-03 2024-03-14 Axsome Therapeutics Metodos y composiciones para mejorar biomarcadores asociados con riesgo cardiovascular usando carbamato de (r)-2-amino-3-fenilpropi lo.
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
EP4615426A1 (en) * 2022-11-07 2025-09-17 Axsome Therapeutics Compositions and methods for treating insomnia
EP4626417A1 (en) * 2022-11-30 2025-10-08 Axsome Therapeutics Methods and compositions for improving driving performance
US12102609B2 (en) 2022-12-30 2024-10-01 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12036194B1 (en) 2022-12-30 2024-07-16 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
WO2024145545A2 (en) * 2022-12-30 2024-07-04 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12090126B2 (en) 2022-12-30 2024-09-17 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12005036B1 (en) 2022-12-30 2024-06-11 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US12064411B1 (en) * 2022-12-30 2024-08-20 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
US11771666B1 (en) 2022-12-30 2023-10-03 Axsome Malta Ltd. Methods of administering solriamfetol to lactating women
KR20260016554A (ko) * 2023-05-30 2026-02-03 액섬 테라퓨틱스, 인크. 폐쇄성 수면 무호흡 및 과도한 주간 졸림증과 연관된 인지 장애를 갖고 있는 대상체에서의 인지 장애를 치료하기 위한 솔리암페톨
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases
WO2025064549A1 (en) * 2023-09-18 2025-03-27 Axsome Therapeutics, Inc. Solriamfetol for improving cognitive health in apnea patients

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
DE9311004U1 (de) 1993-07-23 1993-10-14 Mauser-Werke GmbH, 50321 Brühl Palettencontainer
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6472431B2 (en) 1998-12-23 2002-10-29 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
CA2439475C (en) 2001-02-27 2010-05-18 Carlos R. Plata-Salaman Carbamate compounds for use in preventing or treating bipolar disorder
MXPA03007720A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad.
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
NZ537543A (en) 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
MX340591B (es) 2010-05-04 2016-07-15 Jazz Pharmaceuticals Inc * Formulaciones de liberacion inmediata y formas de dosis de gamma-hidroxibutirato.
EP2392325A1 (en) 2010-06-04 2011-12-07 Universitätsklinikum Münster Compounds for the prevention and/or treatment of osteoarthrosis
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
RU2689984C2 (ru) 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
KR20160030955A (ko) 2013-07-12 2016-03-21 에스케이바이오팜 주식회사 금연의 촉진
EP3021838B1 (en) 2013-07-18 2020-05-27 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function

Also Published As

Publication number Publication date
WO2018222954A1 (en) 2018-12-06
US20200163927A1 (en) 2020-05-28
MX2019014409A (es) 2022-03-17
EP3630072A4 (en) 2021-03-10
KR102726728B1 (ko) 2024-11-05
US20200281886A1 (en) 2020-09-10
US20240180866A1 (en) 2024-06-06
AU2018278332B2 (en) 2022-05-19
US11648232B2 (en) 2023-05-16
JP2020528075A (ja) 2020-09-17
CA3065522A1 (en) 2018-12-06
EP3630072A1 (en) 2020-04-08
NZ760594A (en) 2025-05-02
US10912754B2 (en) 2021-02-09
US20240189270A1 (en) 2024-06-13
US10959976B2 (en) 2021-03-30
KR20230145525A (ko) 2023-10-17
PH12019502723A1 (en) 2020-07-13
KR20200016889A (ko) 2020-02-17
BR112019025286A2 (pt) 2020-06-23
US20240033243A1 (en) 2024-02-01
CN111201014A (zh) 2020-05-26
US20250114322A1 (en) 2025-04-10
KR20240162165A (ko) 2024-11-14
AU2018278332A1 (en) 2020-01-30
MY203401A (en) 2024-06-26
US11865098B1 (en) 2024-01-09
US20210205257A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
MX390786B (es) Métodos y composiciones para tratar somnolencia excesiva.
CY1124121T1 (el) Εκλεκτικοι ρυθμιστες υποδοχεα σφιγγοσινης 1 φωσφορικης και μεθοδοι χειρομορφικης συνθεσης
CY1125178T1 (el) Διεγερτες της sgc
CY1123367T1 (el) Μεθοδοι και συνθεσεις για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α)
SA521422063B1 (ar) تركيبات وطرق لتعديل نشاط ديهيدروجيناز بسلسلة قصيرة
MX388693B (es) Composiciones de nanoparticulas para terapia sostenida.
UY38670A (es) Inhibidores de dihidroorotato deshidrogenasa
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201792673A1 (ru) 3-арил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MX379318B (es) Metodos para tratar trastornos de sueño de ritmo circadiano.
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
BR112018006445A2 (pt) métodos para tratar distrofia muscular
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
BR112022004576A2 (pt) Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
MX2021006463A (es) Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3.
EP4316592A3 (en) Carbamoyl phenylalaninol compounds and uses thereof
EP4345110A3 (en) Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
GEAP202415966A (en) Inhibitors of adrenoreceptor adrac2
MX2015009696A (es) Composiciones estables que comprenden heparinoide, anestesico de accion aguda y regulador de ph.
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
WO2014116556A3 (en) Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn
EA201792418A1 (ru) Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности